• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

伊朗库尔德斯坦省前列腺癌的总生存率和预后因素:一项基于人群的研究(2011-2018 年)。

Overall survival and prognostic factors prostate cancer in Kurdistan Province-Iran: a population-based study (2011-2018).

机构信息

Social Determinants of Health Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran.

Department of Epidemiology and Biostatistics, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran.

出版信息

BMC Cancer. 2021 Dec 8;21(1):1314. doi: 10.1186/s12885-021-09078-8.

DOI:10.1186/s12885-021-09078-8
PMID:34876069
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8653556/
Abstract

BACKGROUND

The population-based survival rate is affected by the quality and effectiveness of health care systems. Overall, the survival of prostate cancer (PC) patients has improved over the past two decades worldwide. This study aimed to determine the overall survival rate and correlate it with the prognostic factors in patients with PC diagnosed in Kurdistan province.

METHODS

In a retrospective cohort study, 410 PC patients registered in Kurdistan province population-based cancer registry from March 2011 to 2018 were recruited. Kaplan-Meier method and log-rank test were used to analyze the overall survival rates of PC patients. A Multivariate Cox regression model was used to determine adjusted hazard ratios for different variables.

RESULTS

Of 410 patients with PC, 263 (64.1%) died within seven years due to the disease. The 1, 3, and 5 years survival rates were 93, 64.1, and 40.7%, respectively. According to the results of multiple Cox regression, the following factors were significantly related to PC survival: age at diagnosis (≥81-years old) (HR=2.23, 95% CI: 1.23-4.42) and 71-80 years old was (HR=1.26, 95% CI: 1.12-2.31), occupation (employee) (HR=0.42, 95% CI: 0.20-0.87), educational level: academic (HR=0.78, 95% CI: 0.64-0.91), AJCC stage of disease (HR=2.18, 95% CI: 1.9-3.68), Gleason score ≥ 9 (HR=7.12, 95% CI: 5.35-10.28), and Gleason score= 8 (HR=4.16, 95% CI: 2.50-6.93). There was less mortality rate among the patients who had received active care, radical prostatectomy, radiotherapy, combined treatment, and orchiectomy had a lower mortality rate than those who received no treatment (P<0.05).

CONCLUSIONS

This study demonstrated that factors such as age at diagnosis, level of education, occupation, AJCC stage of disease, Gleason score, and type of treatments were influential factors in the survival of PC patients in Kurdistan province and needed more attention.

摘要

背景

基于人群的生存率受到医疗保健系统的质量和效果的影响。总体而言,在过去的二十年中,全世界前列腺癌(PC)患者的生存率有所提高。本研究旨在确定在库尔德斯坦省诊断出的 PC 患者的总体生存率,并将其与预后因素相关联。

方法

在一项回顾性队列研究中,招募了 2011 年 3 月至 2018 年在库尔德斯坦省人群癌症登记处登记的 410 名 PC 患者。使用 Kaplan-Meier 方法和对数秩检验分析 PC 患者的总体生存率。使用多变量 Cox 回归模型确定不同变量的调整后危险比。

结果

在 410 名 PC 患者中,有 263 名(64.1%)在 7 年内因疾病死亡。1、3 和 5 年的生存率分别为 93、64.1 和 40.7%。根据多 Cox 回归的结果,以下因素与 PC 生存显著相关:诊断时的年龄(≥81 岁)(HR=2.23,95%CI:1.23-4.42)和 71-80 岁(HR=1.26,95%CI:1.12-2.31),职业(雇员)(HR=0.42,95%CI:0.20-0.87),教育程度:学术(HR=0.78,95%CI:0.64-0.91),AJCC 疾病分期(HR=2.18,95%CI:1.9-3.68),Gleason 评分≥9(HR=7.12,95%CI:5.35-10.28)和 Gleason 评分=8(HR=4.16,95%CI:2.50-6.93)。接受积极治疗、根治性前列腺切除术、放疗、联合治疗和睾丸切除术的患者死亡率较低,而未接受治疗的患者死亡率较高(P<0.05)。

结论

本研究表明,诊断时的年龄、教育程度、职业、AJCC 疾病分期、Gleason 评分和治疗类型等因素是影响库尔德斯坦省 PC 患者生存的因素,需要更多关注。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9330/8653556/aa9220713423/12885_2021_9078_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9330/8653556/fe209cbbed90/12885_2021_9078_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9330/8653556/ce281ffd4a90/12885_2021_9078_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9330/8653556/a6fcefde60df/12885_2021_9078_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9330/8653556/aa9220713423/12885_2021_9078_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9330/8653556/fe209cbbed90/12885_2021_9078_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9330/8653556/ce281ffd4a90/12885_2021_9078_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9330/8653556/a6fcefde60df/12885_2021_9078_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9330/8653556/aa9220713423/12885_2021_9078_Fig4_HTML.jpg

相似文献

1
Overall survival and prognostic factors prostate cancer in Kurdistan Province-Iran: a population-based study (2011-2018).伊朗库尔德斯坦省前列腺癌的总生存率和预后因素:一项基于人群的研究(2011-2018 年)。
BMC Cancer. 2021 Dec 8;21(1):1314. doi: 10.1186/s12885-021-09078-8.
2
New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer.新的前列腺癌分级系统可预测 Gleason 评分 8-10 级前列腺癌手术后的长期生存情况。
Eur Urol. 2017 Jun;71(6):907-912. doi: 10.1016/j.eururo.2016.11.006. Epub 2016 Nov 19.
3
Prognostic factors and survival of colorectal cancer in Kurdistan province, Iran: A population-based study (2009-2014).伊朗库尔德斯坦省结直肠癌的预后因素与生存率:一项基于人群的研究(2009 - 2014年)
Medicine (Baltimore). 2017 Feb;96(6):e5941. doi: 10.1097/MD.0000000000005941.
4
Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy.高危前列腺癌定义的异质性及其对根治性前列腺切除术后死亡率的不同影响。
Eur Urol Oncol. 2018 Jun;1(2):143-148. doi: 10.1016/j.euo.2018.02.004. Epub 2018 May 15.
5
Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series.根治性前列腺切除术治疗 pT3N0 前列腺癌患者中辅助与早期挽救性放疗的长期影响:多机构系列研究结果。
Eur Urol. 2017 Jun;71(6):886-893. doi: 10.1016/j.eururo.2016.07.028. Epub 2016 Jul 30.
6
Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.用于预测高危前列腺切除队列中前列腺癌死亡率的经验证的临床和基因组风险分层工具的综合价值。
Eur Urol. 2015 Feb;67(2):326-33. doi: 10.1016/j.eururo.2014.05.039. Epub 2014 Jul 2.
7
Age-adjusted Charlson comorbidity index is a significant prognostic factor for long-term survival of patients with high-risk prostate cancer after radical prostatectomy: a Bayesian model averaging approach.年龄校正的查尔森合并症指数是高危前列腺癌患者根治性前列腺切除术后长期生存的重要预后因素:一种贝叶斯模型平均法。
J Cancer Res Clin Oncol. 2016 Apr;142(4):849-58. doi: 10.1007/s00432-015-2093-0. Epub 2015 Dec 12.
8
The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.根治性前列腺切除术后前列腺特异性抗原持续存在对预测淋巴结阳性前列腺癌患者临床进展和癌症特异性死亡率的作用。
Eur Urol. 2016 Jun;69(6):1142-8. doi: 10.1016/j.eururo.2015.12.010. Epub 2015 Dec 31.
9
Prognostic Factors for Biochemical Recurrence More than 10 Years after Radical Prostatectomy.根治性前列腺切除术后 10 年以上生化复发的预后因素。
J Urol. 2017 Jan;197(1):143-148. doi: 10.1016/j.juro.2016.07.004. Epub 2016 Jul 11.
10
Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.根治性前列腺切除术是治疗标本中存在高病理 Gleason 评分前列腺癌的有效方法。
BJU Int. 2013 May;111(5):723-30. doi: 10.1111/j.1464-410X.2012.11114.x. Epub 2012 Apr 4.

引用本文的文献

1
Nanoparticle-Based Approaches in the Diagnosis and Treatment of Brain Tumors.基于纳米颗粒的脑肿瘤诊断与治疗方法
J Clin Med. 2024 Dec 6;13(23):7449. doi: 10.3390/jcm13237449.
2
The economic burden of prostate cancer in Iran: a cross-sectional cost-of-illness study.伊朗前列腺癌的经济负担:一项横断面疾病成本研究。
BMC Res Notes. 2024 Sep 17;17(1):268. doi: 10.1186/s13104-024-06913-6.

本文引用的文献

1
Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study.开始雄激素剥夺治疗后使用他汀类药物的前列腺癌预后。一项基于人群的队列研究。
Prostate Cancer Prostatic Dis. 2021 Sep;24(3):917-924. doi: 10.1038/s41391-021-00351-2. Epub 2021 Mar 31.
2
Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England.转移性去势抵抗性前列腺癌(mCRPC)患者的黑人和白人的总生存情况:英国最大医疗信托机构 20 年回顾性分析。
Prostate Cancer Prostatic Dis. 2021 Sep;24(3):718-724. doi: 10.1038/s41391-020-00316-x. Epub 2021 Jan 21.
3
Survival Rate of Prostate Cancer in Asian Countries: A Systematic Review and Meta-Analysis.
亚洲国家前列腺癌的生存率:一项系统评价与荟萃分析。
Ann Glob Health. 2020 Jan 2;86(1):2. doi: 10.5334/aogh.2607.
4
Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates.近期全球前列腺癌发病率和死亡率模式。
Eur Urol. 2020 Jan;77(1):38-52. doi: 10.1016/j.eururo.2019.08.005. Epub 2019 Sep 5.
5
A systematic review and meta-analysis on incidence of prostate cancer in Iran.伊朗前列腺癌发病率的系统评价与荟萃分析。
Health Promot Perspect. 2019 May 25;9(2):92-98. doi: 10.15171/hpp.2019.13. eCollection 2019.
6
Cancer treatment and survivorship statistics, 2019.2019 年癌症治疗与生存统计
CA Cancer J Clin. 2019 Sep;69(5):363-385. doi: 10.3322/caac.21565. Epub 2019 Jun 11.
7
Epidemiology of Prostate Cancer.前列腺癌流行病学
World J Oncol. 2019 Apr;10(2):63-89. doi: 10.14740/wjon1191. Epub 2019 Apr 20.
8
Exosome proteomic analyses identify inflammatory phenotype and novel biomarkers in African American prostate cancer patients.外泌体蛋白质组分析鉴定非裔美国前列腺癌患者的炎症表型和新型生物标志物。
Cancer Med. 2019 Mar;8(3):1110-1123. doi: 10.1002/cam4.1885. Epub 2019 Jan 8.
9
Estimating the Cost of Illness of Prostate Cancer in Iran.估算伊朗前列腺癌的疾病经济负担。
Clin Ther. 2019 Jan;41(1):50-58. doi: 10.1016/j.clinthera.2018.11.001. Epub 2018 Dec 10.
10
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.